Afya's Tightrope: An EnMed Tailwind, an AI Squeeze, and a 106% Cash Return

Brazil's medical-education and physician-tools leader holds growth steady in H1 2026, monetizes a court injunction with patience, and admits consumer AI is now its chief competitive threat in clinical decision support.

AFYA · Earnings Call · 2026-08-13

Afya's H1 2026 report is, on its face, more of the same resilience: revenue +7% to BRL 1.985 billion, adjusted EBITDA +3% to BRL 918 million, EPS +9% to BRL 5.10, and operating cash conversion of 87.8%. The adjusted EBITDA margin contracted 190bp to 46.2%, which management squarely attributes to the investment cycle in continuing education and medical practice solutions — the same integration-driven platform push flagged in Q1 2026 as “how can we integrate all of the products and services that we are offering” — Virgilio Deloy Gibbon, Chief Executive Officer · 2026-03-12 for the physician. But beneath the steady print, three developments give this quarter genuine texture: a regulatory reversal from a court injunction, an unusually candid admission that consumer AI tools are eroding a flagship product, and a tax resolution that beats the company's own prior guidance.

The EnMed reversal: a regulated tailwind, carefully discounted

The most distinctive new event is the court ruling. An analyst's question on “the new injunction from last week that suspended the EnMed restrictions” — Virgilio Deloy Gibbon, Chief Executive Officer (CEO) · 2026-08-13 prompted the CEO to confirm that all previously prohibited seats now return to the institutions. This is a genuinely new, company- and sector-specific catalyst — the injunction keyword is new to Afya's trajectory this quarter, distinct from the earlier "ENAMED"-related litigation the company discussed in Q1 2026. Yet management was deliberately measured about the benefit. With intake already largely complete — “we are very advanced on the intake process... we will leave some of them unfulfilled. This will not impact not even positive, not even negative to our results on the second half” — Virgilio Deloy Gibbon, Chief Executive Officer (CEO) · 2026-08-13 — the upside is structural and multi-year rather than an immediate H2 boost. It also confirmed the new EnMed cycle (results due in early December) will be treated separately from the overturned prior-year decision, so the long regulatory overhang remains only partially cleared.

AI at the gate: Whitebook meets the chatbots

The most strategically interesting moment came from the CFO describing why the flagship clinical decision product, Whitebook, continues to lose paying users. This is the first quarter where the company explicitly named consumer AI as the competitive cause:

These pushbacks in terms of active payers are due to the competitions by the AI tools that are pressuring the number of payers. What we decided that we would to reduce a little bit the ticket on that and increase functionalities embedded on the Whitebook.
Luis Andre Blanco, Chief Financial Officer (CFO) · 2026-08-13

This is a meaningful strategic inflection. As recently as Q4 2025, the company framed Whitebook's subscriber losses as a self-inflicted price-mix decision — “we changed our prices at the end of last year... we lost freemium users at that moment” — Virgilio Gibbon, Chief Executive Officer · 2025-11-12. Now the Whitebook decline is attributed to external AI disruption, a far harder problem to price away. The response — cut the ticket, add bundled functionality — acknowledges that standalone clinical-decision apps now compete directly with general-purpose generative AI, a theme the global market is simultaneously punishing in pure-play AI infrastructure names (the 30-day tape shows widespread AI data centers selling off) even as physicians gravitate toward them. Notably, the company's offsetting pillar is clinical management: iClinic-driven active payers grew 20% to over 50,000, even as total segment MAU fell 8%. The strategic bet is that embedding clinical decision support inside the practice-management system — the workflow, not the tool — is where durable value lies.

Tax clarity and a 106% cash return

The third development is the Pillar Two resolution. For four consecutive calls, management flagged that Brazil's minimum top-up tax would push the effective rate toward 15% — “from 2026 onwards, the effective tax rate would converge to 15%” — Luis Andre Blanco, Chief Financial Officer · 2025-11-12 was the line in November. This quarter, new regulatory guidance changed the arithmetic: the CFO reported a ~BRL 20 million favorable effect from releasing the 2025 provision, since actual disbursement was only ~BRL 8-9 million, and guided to an effective tax rate closer to 10% for 2026 — “we see an opportunity regarding the payments that we should do regarding the 2025 taxations... reducing the provision amount that we had on our balance sheet” — Luis Andre Blanco, Chief Financial Officer (CFO) · 2026-08-13. That is a tangible reversal of a previously expected headwind. The cash story reinforced the allocation discipline the company has preached since IPO. In H1, Afya returned BRL 448 million to shareholders — “we distribute almost 100% of actually more than 100% of the cash that we generated to our shareholders through buyback and dividends” — Virgilio Deloy Gibbon, Chief Executive Officer (CEO) · 2026-08-13 — representing 106% of cash flow to equity, while holding net debt roughly flat at BRL 1.394 billion and leverage at 0.8x. With 2.6 million of the 4 million-share buyback consumed and the BRL 307 million dividend paying out 40% of 2025 net income, the company is executing its stated framework: pursue M&A only above a 20% unlevered IRR threshold, else return capital. Net, this is a company in a calm but genuine strategic transition — fending off AI competition at the edge of its physician ecosystem, monetizing a regulatory reversal with patience, and converting tax uncertainty into a cleaner earnings profile. The margin compression from the investment cycle is the price of repositioning, and the cash flow to equity keeps funding the return of capital. For investors, the question is whether the Whitebook AI squeeze is a manageable mix shift or the leading edge of a broader commoditization — and Afya's answer is to lean harder into integrated clinical management and scale.